Columns | Clinical Trial Insights

Study uncovers realistic goals in efforts to embrace decentralized clinical trials.

Self-determined eligibility and the influence of clinical care challenge this flawed figure.

The struggle to translate promising movements in R&D.

AI presents rare opportunity to assess the scope of this longtime challenge.

Study holds new benchmarks and improvement opportunities.

Record numbers point to new R&D operating environment, driven by a changing community of sponsors.

It’s time to establish standard practices to return clinical trial results summaries to patients.

New study reveals that inconsistent, tactical, and reactive outsourcing practices predominate.

Reexamining traditional cycle-time reduction strategies is critical for sponsors, CROs, and sites.

Amid industry feedback that the growing volume and diversity of eClinical data collected for studies is taxing cycle times, two studies highlight the need to optimize protocol design and executional complexity to overcome these data management burdens.

Study examines the growing integration of real-world data and evidence and the remaining roadblocks to adoption.    

Recent study, and others in literature, inform misconceptions around physician and nurse involvement in clinical trials. 

Traditional and new players are seeing growth and opportunity as the integration of clinical research and healthcare intensifies.    

The nascent and fragmented global community of investigators is showing signs of scaling and maturing.

Examining the evolution of protocol design and collaboration executing strategies.

Recent studies may help break down barriers to implementing patient-centric initiatives.

New study finds that the long-strained relationship between sites and institutional review boards may finally be improving.

New study finds that most biopharma companies are now using a standard set of key performance indicators.

Research reveals a need for sponsors to be much more consistent, disciplined and focused in their CRO usage.

Work burden and performance hurt by technology incompatibility.

Study provides real metrics on the trial-scope affects of protocol changes-shedding fresh light on the importance of adopting new strategies to reduce select amendments.

Despite wealth of data collected, many inefficiencies exist in the site-sponsor transfer of insights from clinical trials.

Study uncovers subtle distinctions in attitudes and perceptions among the two groups.

Survey provides new benchmarks on e-solutions adoption, but actual impact data remains elusive.

While still early days, key metrics can be collected in three broad areas

Study takes rare look at the financial and resource burden for sites in managing regulatory compliance.

Study shows that industry contributions to R&D go well beyond the applied area of clinical testing.

Research shows that the potential of integrated alliances remains elusive in the near term.

Unique feedback from patient survey could help inform future clinical supply design and implementation.

Science exhibit will give children and young adults a rare look inside clinical trial patient experience.

Half of all drugs in clinical testing are interrupted by in-licensing, co-development, joint venture and M&A arrangements – and they are taking significantly more time to develop.

A discussion of summary findings from the CISCRP 2013 Perceptions & Insights Study

Adaptive trial designs have the potential to transform success rates, but require new operating strategies and practices.

Compliance with reporting clinical trial results is low, and an even larger opportunity is being missed.

Research shows four factors best predict successful patient enrollment in clinical trials.

A new study shows that the cost of implementing protocol amendments should be weighed carefully.

Direction from regulatory agencies would help eradicate wasteful 100 percent source data verification.

Doing more harm than good will ultimately force human subject protection system reform.

Why investigative sites are at financial risk and how it may effect sponsors and CROs.

FDA and EMA may issue new guidelines on sponsor-CRO governance and responsibilities.

A recent survey indicates pharmacists should provide more clinical trial information to patients.

Patients share factors that most inform, educate, and motivate clinical trial participants.

Spending on research exceeds $35 billion, and clinical grant spending now tops $11 billion.

Economic factors and sponsor practices will dramatically alter the investigative site landscape.

The public would be best served if both recognize their own questionable practices.

Out of necessity, providers may finally become valued strategic partners.

Drug development, largely immune to past economic downturns, now faces a different climate.

A look at the vague but time consuming requirements imposed on sites and efforts to ease the burden.

The public considers clinical research important, but they're not fans of the people behind it.

Today's problem-plagued feasibility assessment process is in need of repair.

More complex and demanding protocols are hurting clinical trial performance and success.

Today's sponsors are waking up to the fact that changes made between phases can positively impact R&D.

Lack of minority clinical investigators behind dearth of minority subjects in trials.

Creating sustainable change is the key to fixing this broken process and advancing clinical research.

Individual countries hold the key to finding hot spots in growth regions like Central and Eastern Europe.

Today's CRAs must redefine their roles in the face of changing industry expectations and new technologies.

A new study from Tufts highlights employee and fiscal growth in the industry from 2002 to 2005.

After parting ways in the late 90s, academic medical centers are revisiting industry-sponsored clinical trials.

With today's clinical investigators awash in regulatory burdens, it's high time sponsors provided a lifeboat.

Generalizing fastest drug development strategies and practices.

Successful efforts of the organ donation sector could serve as a model for rebuilding public trust.

Yesterday's SMOs have given way to a new service provider that should be recognized.

With outsourcing on the rise, it's time companies reevaluated the role of CROs.

Online trial registries alone will not succeed at rebuilding public confidence.

Lack of adequate and attentive support is preventing some sites from fully taking advantage of EDC and ePRO technologies.

A growing trend in the industry has many pharmaceutical companies looking to manage the changing mix of global clinical trial locations.

Performance, compliance, and financial pressures are hitting investigators hard. What can sponsors and CROs do to help the situation?

The FDA's Critical Path Initiative acknowledges long-standing and widely accepted challenges facing the clinical research enterprise and identifies several opportunity areas that may help to address these challenges.

Based on the numbers, sponsors will rapidly change their clinical trials midstream.